Written Informed Consent Sample Clauses

The Written Informed Consent clause requires that a party must obtain explicit, documented permission from another party before proceeding with certain actions or decisions. In practice, this means that consent must be provided in writing—such as through a signed form or email—after the consenting party has been fully informed of all relevant details and potential risks. This clause ensures that all parties are aware of and agree to specific terms or activities, thereby reducing misunderstandings and providing clear evidence of consent if disputes arise.
Written Informed Consent. It is the responsibility of the Investigator to obtain signed written informed consent from each potential study patient prior to the conduct of any screening or other study procedures. This written informed consent will be obtained after the methods, objectives, and potential risks of the study have been fully explained to the potential patient. The Investigator must explain to each patient that he or she is completely free to refuse to enter the study or to withdraw from it at any time. The patient should also be asked in the ICF for permission for the Principal Investigator or their designee to contact the patient’s other personal physicians, as appropriate, concerning participation in the study. The method of obtaining and documenting informed consent and the contents of the ICF will comply with ICH GCP guidelines, the requirements of 21 CFR Part 50, “Protection of Human Patients,” the Health Insurance Portability and Accountability Act (HIPAA) regulations, and all other applicable regulatory requirements. A properly executed written ICF shall be read, signed, and dated by each patient prior to entering the trial or prior to performing any study procedure. The original signed and dated ICF will be kept on file at the study site. Patients will be given a copy of the signed ICF and will be informed of any new developments during the course of the study that might influence their continued participation in the study. The Investigator or a qualified designee will be available to answer each patient’s questions throughout the study, and all questions must be answered to the patient’s satisfaction. If the protocol is amended and a revised ICF is introduced during the study, each patient’s further consent must be obtained. The new version of the ICF must be approved by the EC, prior to subsequently obtaining each patient’s consent. Receipt of written informed consent will be documented in each patient’s or potential patient’s CRF. The signed ICF must remain in each patient’s study file and must be available for verification by study monitors at all times. Separate written, signed informed consent must be obtained if the patient is to participate in the optional pharmacogenomic assessment.
View SourceView Similar (4)
Written Informed Consent. Prior to enrolling a trial participant, the investigator(s) will ensure that the participant is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Participants must also be notified that they are free to discontinue from the study at any time. The participant should be given the opportunity to ask questions and allowed time to consider the information provided. When the participant decides to participate in the trial, the participant (or the participant’s, parent or legally authorized representative) must provide signed and dated informed consent. The written consent must be obtained before conducting any study procedures. The investigator must document the consent process in the participant’s source records. The investigator must maintain the original, signed Informed Consent Form. A copy of the signed Informed Consent Form must be given to the participant or to the participant’s parent or legally authorized representative. Throughout the trial participants should be informed of any changes made to the study and as new safety and or risk information becomes known. The provision of this information will be documented in the participant’s source records, and when applicable, an updated ICF will be provided.
View Source
Written Informed Consent. The Investigator(s) at each center will ensure that the patient (as age appropriate) and the patient’s parent(s) or legal guardian(s) are given full and adequate oral and written information about the nature, purpose, possible risk, and benefit of the study. Patients and their parent(s) or legal guardian(s) must also be notified that they are free to discontinue from the study at any time. The patients and their parent(s) or legal guardian(s) should be given the opportunity to ask questions and allowed time to consider the information provided. The patient’s signed and dated informed consent form must be obtained before conducting any study procedures. Assent from patients will also be obtained at Screening or at any time during the study, if possible, in an age-appropriate manner, per federal regulations (Code of Federal Regulations, Title 45, Part 46.408) and local requirements. The Investigator(s) must maintain the original, signed informed consent form. A copy of the signed informed consent form must be given to the patient and the patient’s parent(s) or legal guardian(s).
View Source
Written Informed Consent. The Principal Investigator will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risk, and benefit of the study. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided before signing the ICF. As additional assessments, the ICF will contain provisions for optional consent for the collection of blood samples for hormone and biomarker testing during screening and the collection of breast milk for biobanking purposes. The ICF, as specified by the clinical site’s IRB, must follow the Protection of Human Subjects regulations listed in the Code of Federal Regulations, Title 21, Part 50. The subject’s signed and dated informed consent must be obtained before conducting any study procedures. The Principal Investigator(s) must maintain the original, signed ICF. A copy of the signed ICF must be given to the subject.
View Source
Written Informed Consent. The investigator(s) at each center will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided. The subject’s signed and dated informed consent must be obtained before conducting any study procedures. The investigator(s) must maintain the original, signed ICF. A copy of the signed ICF must be given to the subject.
View Source
Written Informed Consent. The Principal Investigator at each center will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risk and possible benefit of the study. Subjects must also be notified that they are free to withdraw from the study at any time. Subjects should be given the opportunity to ask questions and allowed time to consider the information provided. Before participating in any study-related activity, voluntary informed consent must be documented by the use of a written ICF approved by the IRE or IEC and signed and dated by the subject or the subject's legally authorized representative at the time of consent. The original signed and dated ICF will be retained with the study records, and a copy of the signed ICF will be given to the subject or the subject's legally authorized representative.
View Source
Written Informed Consent. The Investigator(s) at each center will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided. This process should be recorded in the subject’s source documentation. The subject’s signed and dated informed consent must be obtained before conducting any study procedures. Documentation of the consenting process must be recorded in the subject’s source documents. The Investigator(s) must maintain the original, signed Informed Consent Form. A copy of the signed Informed Consent Form must be given to the subject, and this must be documented in the subject’s source documents.
View Source
Written Informed Consent. ‌ The schedule of study activities (including assessments, tests, exams, disease assessments, and study drug administration) beginning with screening and continuing through the end of study are outlined in Table 3. A written, signed informed consent form (ICF) must be obtained from each subject prior to performing any study related procedure (e.g., ▇▇▇▇▇ ▇▇▇▇▇, clinical laboratory sampling, or photography). The Principal Investigator at each center will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided. The subject’s signed and dated informed consent must be obtained before conducting any study procedures. The Principal Investigator must maintain the original, signed Informed Consent Form. A copy of the signed Informed Consent Form must be given to the subject.
View Source
Written Informed Consent. It is the responsibility of the investigator to obtain signed written informed consent from each potential study patient prior to the conduct of any screening or other study procedures. This written informed consent will be obtained after the methods, objectives, and potential risks of the study have been fully explained to the potential patient. The investigator must explain to each patient that he or she is completely free to refuse to enter the study or to withdraw from it at any time. NOTE: Patients on serotoninergic medications (e.g., triptans) should be warned of a potential serious drug interaction and should be advised to contact their study site immediately if they experience any symptoms that might represent possible serotonin syndrome, including fever, confusion or agitation, hallucinations, sweating, high or low blood pressure, rapid heart rate, tremor, muscle rigidity or nausea, vomiting or diarrhea. Patients on MAOIs should not be considered for the study, and MAOIs should not be initiated during the study due to the additional safety concerns posed by this class of medication when used in combination with other serotoninergic drugs (such as cyclobenzaprine). The patient should also be asked in the Informed Consent Form (ICF) for permission for the principal investigator or his designee to contact the patient’s other personal physicians, as appropriate, concerning participation in the study. Separate written, signed informed consent must be obtained if the patient is to participate in the post-study optional pharmacogenomic assessment. The method of obtaining and documenting informed consent and the contents of the ICF will comply with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines, the requirements of 21 CFR Part 50, “Protection of Human Patients,” the Health Insurance Portability and Accountability Act (HIPAA) regulations, and all other applicable regulatory requirements. A properly executed written ICF shall be read, signed, and dated by each patient prior to entering the trial or prior to performing any study procedure. The original signed and dated ICF will be kept on file at the study site. Patients will be given a copy of the signed ICF and will be informed of any new developments during the course of the study that might influence their continued participation in the study. The investigator or a qualified designee will be available to answer each patient’s questions throughout the study, and al...
View Source

Related to Written Informed Consent

  • Informed Consent Principal Investigator shall ensure that the ICF approved by Sponsor, IEC and/or RA is signed on behalf of each Trial Subject before the first Trial related procedure starts for the Trial Subject. 8. Informovaný souhlas. Hlavní zkoušející je povinen zajistit, že před zahájením prvních postupů klinického hodnocení u subjektu klinického hodnocení bude jménem každého subjektu klinického hodnocení podepsán formulář informovaného souhlasu schválený zadavatelem, NEK a/nebo RÚ.

  • Written Approval Except with the prior written approval of Authority, which shall not be unreasonably withheld, conditioned, or delayed, Company will not erect, maintain, or display any signs or any advertising at or on the Premises or Common Use Areas.

  • Disclosure Updates Promptly and in no event later than 5 Business Days after obtaining knowledge thereof, notify Agent if any written information, exhibit, or report furnished to the Lender Group contained, at the time it was furnished, any untrue statement of a material fact or omitted to state any material fact necessary to make the statements contained therein not misleading in light of the circumstances in which made. The foregoing to the contrary notwithstanding, any notification pursuant to the foregoing provision will not cure or remedy the effect of the prior untrue statement of a material fact or omission of any material fact nor shall any such notification have the effect of amending or modifying this Agreement or any of the Schedules hereto.

  • No Conflict; Required Filings and Consents (a) The execution, delivery and performance of this Agreement by the Company do not and will not (i) conflict with or violate the certificate of incorporation or by-laws of the Company, (ii) assuming that all consents, approvals and authorizations contemplated by clauses (i) through (ii) of subsection (b) below have been obtained, and all filings described in such clauses have been made, conflict with or violate any law, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries or by which its or any of their respective properties are bound, or (iii) except as set forth on Section 3.5(a)(iii) of the Company Disclosure Schedule, result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would become a default) or result in the loss of a benefit under, or give rise to any right of modification, termination, cancellation, amendment or acceleration of, or result in the creation of any Encumbrances (other than Encumbrances arising out of this Agreement or restrictions imposed by law) upon any of the assets or properties of the Company or any of its Subsidiaries, under any of the terms, conditions or provisions of any written or oral note, bond, mortgage, indenture, contract, binding commitment, agreement, understanding, lease (including the lease of any store, distribution center, warehouse or corporate offices), license, permit or other instrument or obligation (each, a “Contract”) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or its or any of their respective properties or assets may be bound. (b) The execution, delivery and performance of this Agreement by the Company and the consummation of the Merger by the Company do not and will not require any consent, approval, authorization or permit of, action by, filing or registration with or notification to, any federal, state, local or foreign legislative, executive or regulatory (including stock exchange) authority, agency, court, commission, or other governmental body (each, a “Governmental Entity”), except for (i) the state securities, takeover, tender offer and “blue sky” laws listed on Section 3.5(b) of the Company Disclosure Schedule, and (ii) the filing with the Office of the Secretary of State of the State of Delaware of the Certificate of Merger as required by the DGCL.

  • Required Filings and Consents None of the execution, delivery or performance of this Agreement by the Company, the consummation by the Company of the Offer, the Merger or any other transaction contemplated by this Agreement, or the Company’s compliance with any of the provisions of this Agreement will require (with or without notice or lapse of time, or both) any consent, approval, authorization or permit of, or filing or registration with or notification to, any Governmental Entity, other than (a) the filing and recordation of the Certificate of Merger as required by the DGCL, (b) the Company Stockholder Approval, (c) compliance with any applicable requirements of the HSR Act and other applicable foreign or supranational antitrust and competition laws set forth in Section 4.5 of the Company Disclosure Schedule, (d) compliance with the applicable requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), (e) compliance with the applicable requirements of the Securities Act, (f) compliance with any applicable foreign or state securities or Blue Sky Laws, (g) filings with the United States Securities and Exchange Commission (the “SEC”) as may be required by the Company in connection with this Agreement and the transactions contemplated hereby, (h) such filings as may be required under the rules and regulations of the NYSE and (i) where the failure to obtain such consents, approvals, authorizations or permits of, or to make such filings, registrations with or notifications to any Governmental Entity, individually or in the aggregate, would not reasonably be expected to have a Company Material Adverse Effect.